leukemia

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

...he aplasia, its conditions of onset ( e.g. during leukemia induction therapy, which may be associated with a pre-existing infection), and fever monitoring, associated with pathogen identification in only 25-30% of these cases, leading to emergency requirements in some instances. Based on solid clinical analy...

Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

...d or refractory acuteleukemia, chronic myelogenous leukemia in blast crisis, or advancedmyelodysplastic syndromes. Data from this trial are expectedin 2007. Background on Mitotic Kinesin Inhibitors Since their introduction over 40 years ago, anti-mitotic drugs(taxanes and vinca alkaloids) have advanced the...

MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia

...clinical study fortreatment of chronic lymphocytic leukemia (CLL) and a Phase IIastudy using engineered stem cells for the treatment of primaryPulmonary Arterial Hypertension (PAH). In addition there areadvanced preclinical programs in oncology and regenerativemedicine. More than 16 commercial and academic pa...

Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial

...tudyis divided into two arms, one for treatment of leukemia patientsand the other for treatment of patients with lymphoma and myeloma.For the leukemia arm of the study, patients are currently beingtreated at the tenth dose level, 250 mg twice daily. F...

Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial

...I trial involving patients with chroniclymphocytic leukemia (CLL), according to data presented today byAlan Colowick, M.D., M.P.H., the company's president, oncology, atthe Pan Pacific Lymphoma Conference in Maui, Hawaii. Favorable Pharmacokinetics; Pharmacodynamics Consistent withExpectations A pharmacokine...

Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting

...a subset ofelderly patients with acute myelogenous leukemia (AML) or high-riskmyelodysplastic syndrome (MDS) and unfavorable cytogenetics. The Phase II trial was conducted from March 2004 to May 2006.The study treated 129 patients of 60 years of age or older withpreviously untreated AML or high-risk MDS. Pre...

Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix's AAGP

... the treatment of certain types ofcancers, such as leukemia and other conditions requiring bonemarrow transplant are enormous." For further information, investors are asked to visit theProtoKinetix Investor Relations Hub atwww.agoracom.com/IR/ProtoKinetix or email to PKTX@agoracom.com. About ProtoKinetix:...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...icacy data in older patients withacute myelogenous leukemia (AML) and activity observed in patientswith refractory acute lymphocytic leukemia (ALL). Gliadel(R) Wafer(polifeprosan 20 with carmustine implant) was the subject of twoposters with ...

ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO

...ly in phase 2/3 clinical trials forchronic myeloid leukemia (CML) and Quinamed® is in phase 2clinical development for prostate, breast and ovarian cancers. Thecompany has a significant portfolio of anti-cancer, diabetes andobesity programs, several of which have been partnered withinternational pharmaceut...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

... while transformation fromMDS to acute myelogenous leukemia (AML) occurs in up to 40 percentof patients. The h...with Myelodysplastic Syndromes (MDS), acutemyeloid leukemia (AML) or other solid tumors. A total of fourpatients were enrolled and received study drug. One pati...

MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...icacy data in olderpatients with acute myelogenous leukemia (AML) and activityobserved in patients with refractory acute lymphocytic leukemia(ALL). Gliadel Wafer (polifeprosan 20 with carmustine implant) wasthe subject of two posters with one detailing the impact ofmultimodal therapy that included Gliadel imp...

Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas

... for immunotherapy of B-cell malignanciesincluding leukemia and lymphomas. The study, entitled "The lymphoidce...shownto be effective in eliminating lymphocytes in leukemia and lymphomapatients (1,2,3,4). However, a significant number of patientsrelapse after initial respo...

8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar

...dysplastic syndrome(a type of pre-leukemia) and/or leukemia and 65 cases of secondarytumors in 54 patients were reported among the 995 patients enrolledin studies with BEXXAR. Healthcare providers must be specifically trained to administerBEXXAR. Additional information about the BEXXAR TherapeuticRegimen, in...

Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report

...stablished second-linedrug for chronic myelogenous leukemia has high response rates whengiven to newly diagnosed patients as their first therapy for thedisease, according to early results from a Phase II clinical trialat The University of Texas M. D. Anderson Cancer Center. "Patients taking dasatinib achieve...

Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia

...ed in children withB-precursor acute lymphoblastic leukemia (ALL), producing favorableearly responses in the majority of patients. Elizabeth Raetz, MD,pediatric oncologist at New York University, New York, in an oralpresentation at the 43rd Annual Meeting of the American Society ofClinical Oncology (ASCO) in ...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

...ycin as atreatment for patients with acute myeloid leukemia (AML). Kosan is also testing alvespimycin delivered orally in a Phase 1dose escalation trial on both daily and every other day schedules.While dose escalation continues in this trial, early results haveshown prolonged stable disease in patients with...

ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia

... trial with atacicept in B-cell chroniclymphocytic leukemia (B-CLL) at the American Society of ClinicalOncology (ASCO) 2007 annual meeting. The study included intravenousadministration of higher doses than had been tested in previousstudies. "We found that atacicept was well-tolerated and biologicallyactive ...

Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting

...or the treatment of high-risk MDS and acutemyeloid leukemia (AML), and in combination with valproic acid inadvanced solid tumors. An oral presentation on a study of MGCD0103 inrelapsed/refractory Hodgkin's lymphoma will be presented duringASCO, as will a poster on the use of MGCD0103 as a single agent inpati...

Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting

...itive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib"Abstract Number: 7046Ses...

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

...readilyavailable. Treatment-related acute myeloid leukemia (AML) has occurred inpatients given anthracyclines and/or cyclophosphamide, includinguse with Taxotere(R) in adjuvant therapy for breast cancer. Themost common severe side effects are low white-blood-cell count,anemia, fatigue, diarrhea, and mouth an...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

...5 Philadelphia-positive CML and acutelymphoblastic leukemia (ALL) patients who had failed Gleevec, andwho were...ly in phase 2/3 clinical trials forchronic myeloid leukemia (CML) and Quinamed(R) is in phase 2clinical development for prostate, breast and ovarian cancers. Th...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

...Abl point mutationin patients with chronic myeloid leukemia (CML). The T315I Bcr-Ablmutation is associated wit...5Philadelphia-positive CML and acute lymphoblastic leukemia (ALL)patients who had failed Gleevec, and who were migrated to dasatinibtherapy. • Eight of th...

Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent

...d with MDS willtypically progress to acute myeloid leukemia (AML). Patientsreceiving Revlimid also had a statistically significant overallsurvival advantage. MDS, a cancer in which the bone marrow fails to make enoughfunctioning blood cells, affects 300,000 people worldwide killing60,000 to 70,000 a year. MD...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

...ted forthe treatment of B-cell chronic lymphocytic leukemia (B-CLL) inpatients who have been treated with alkylating agents and who havefailed fludarabine therapy. Determination of the effectiveness ofCampath is based on overall response rates. Comparative, randomizedtrials demonstrating increased survival or...

Telomerase Presentations at the AACR 2007 Annual Meeting

...study of GRNVAC1 inpatients with acute myelogenous leukemia (AML), in the monthsahead. Geron is developing first-in-class biopharmaceuticals for thetreatment of cancer and chronic degenerative diseases, includingspinal cord injury, heart failure, diabetes and HIV/AIDS. Thecompany is advancing an anti-cancer ...

EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers

...ry cells derived from acute andchronic myelogenous leukemia (AML and CML) patients in vitro. MKC-1was also sho...nduces apoptosis both inleukemia cell lines and in leukemia patient samples." Dr. Bray also commented, "These findings further support ourplans to evaluate MKC...

Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR

...s of cancer, including lymphoma, multiple myeloma, leukemia andsolid tumors. The company has an exclusive worldwide licenseagreement with Genentech to develop and commercialize SGN-40.Seattle Genetics also has three other proprietary programs inongoing clinical trials: SGN-33, SGN-35 and SGN-30. In addition,t...

Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting

...GX15-070 (obatoclax), in infantacute lymphoblastic leukemia (ALL). The study was discussed in anoral presentat...sof apoptosis. In this study, researchers obtained leukemia blast cells fromfive infants and one child with primary ALL. The blasts wereexposed to GX15-070 as a...

ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR

...rently approved for the treatmentof a rare form of leukemia and used in the treatment of advancedmultiple myeloma. Differences in the way the two drugs activategenes and in their mechanisms of action suggest that ZIO-101 islikely to be active against cancer cells that are resistant toarsenic trioxide. "These...

Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models

...cluding non-Hodgkin'slymphoma, chronic lymphocytic leukemia and acute lymphocyticleukemia. Single dose treatme...ablished subcutaneous tumors andsystemic tumors in leukemia xenograft models. Anti-CD19 antibody-drug conjugate was well-tolerated and without toxicity in thean...

EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting

...tubuledestabilizing agent) sensitive and resistant leukemia cell lines.Results from in vivo studies also showed that treatment withENMD-1198 prolonged survival rates significantly in vinca alkaloidsensitive and resistant (ALL3, ALL7 and ALL19) preclinical leukemiamodels. "These data further support ENMD-1198...

Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells

...al arsenic) in the treatment of acutepromyelocytic leukemia (APL). The research, conducted by Dr. Ethan Dmitrovsky, and hiscolleagues at Dartmouth Medical School, determined that arseniteselectively destroys APL cells. It was observed that arsenitecauses a form of cell "suicide" in which digestive enzymes us...

Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting

...nt(specifically, diagnoses of chronic lymphocyctic leukemia or lowgrade lymphoma, ongoing hormonal or antibody therapy versus allother eligible patients), and ECOG status (0-1, 2). Demographics were broadly similar between the groups. The mean(SD) age was 64.1 (11.6) years; the most common cancers werenon-sm...

Sunesis Presents Data Supporting SNS-032's Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting

...ncer and a Phase 1 clinical trial in acute myeloid leukemia forits lead compound, SNS-595. SNS-032, Sunesis' CDK inhibitorcompound, is being evaluated in Phase 1 clinical trials in B-cellmalignancies and in advanced solid tumors. The company's Aurorakinase inhibitor, SNS-314 is expected to begin Phase 1 clini...

Rigel to Present New Research Programs at AACR Meeting

...potent anti-tumor activity in acute myelogenous leukemia (AML) Session ID: Targeted Agents and Other Novel Therapies, Abstract Number 1817 Monday, April 16, 2007 1:00pm-5:00pm (by Merck Serono) Preclinical evaluation of the orally available Aurora Kinase inhibitor AS703569 to support the sel...

Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study

... the treatment of all phases ofPh+ chronic myeloid leukemia (CML). Glivec is also approved in theEU, US and ot...tients with newlydiagnosed Ph+ acute lymphoblastic leukemia (Ph+ ALL) in combinationwith chemotherapy and as a single agent for patients with relapsedor refract...

Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting

...tivity against human Ascenta leukemia and lymphoma cells. Therapeutics--------- --------- ---------------------------------- --------------Date Time Session Type/Location Abstract #------...

Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research

...ncer and a Phase 1 clinical trial in acute myeloid leukemia forits lead compound, SNS-595. SNS-032, Sunesis' CDK inhibitorcompound, is being evaluated in Phase 1 clinical trials in B-cellmalignancies and in advanced solid tumors. The company's Aurorakinase inhibitor, SNS-314 is expected to begin Phase 1 clini...

CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting

... with Bortezomib in human chronic lymphocytic leukemia (CLL) cells in association with NF-.B inactivation," (Abstract #1835) during the conference's Targeted Agents and Other Novel Therapies poster session on Monday, April 16th in the Exhibit Hall, Poster Section 7 on Poster B...

Innovive Pharmaceuticals Announces Additional Data Presentations at American Association for Cancer Research Annual Meeting

...f T cell acute lymphoblastic leukemia cell lines expressing the NUP214-ABL1 fusion kinase"Abstract Number: 1825Session: Poster Section 7, Clinical Research 8, Poster Board #11Session Date and Time: Monday, April 16, 2007, 8:...

Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting

...ally with Bortezomib in human chroniclymphomocytic leukemia (CLL) cells in association with NF-kBinactivation" will be presented in a poster session on Monday,April 16 from 8:00 am - 12:00 pm. Dr. Yun Dai et al of the VirginiaCommonwealth University and Massey Cancer Center are authors. Abstract #2484 "His...

Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

...aclinical trial of L- Annamycin in pediatric acute leukemia patientsin 1Q 2007 and initiated a trial in adult relapsed or refractoryacute lymphoblastic leukemia patients in 4Q 2005. L-Annamycin, anew compound from the anthracycline family of proven anti-cancerd...

Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting

...npatients with acute leukemia, chronic myelogenous leukemia oradvanced myelodysplastic syndromes. Data from this trial areexpected in 2007. Since their introduction over 40 years ago, anti-mitotic drugs(taxanes and vinca alkaloids) have advanced the treatment of cancerand are commonly used for the treatment ...

Nereus Pharmaceuticals to Present Data at the American Association for Cancer Research 2007 Annual Meeting

...ng markedly enhancedpotency and apoptosis in human leukemia cells treated with NPI-0052and various histone dea...rgizes withHDAC inhibitors to trigger apoptosis in leukemia cells Claudia Miller, Joya Chandra. University of Texas, M.D. AndersonCancer Center, Houston, TX T...

Leukemic Cells Find Safe Haven in Bone Marrow

...to help cure some children with acutelymphoblastic leukemia (ALL) because molecules released by certaincells in the bone marrow counteract the effect of that drug,according to investigators at St. Jude Children's ResearchHospital. The researchers showed that mesenchymal cells in the bone marrowcreate a prote...

Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility

...ncer and a Phase 1 clinical trial in acute myeloid leukemia forits lead compound, SNS-595. SNS-032, Sunesis' CDK inhibitorcompound, is being evaluated in Phase 1 clinical trials in B-cellmalignancies and in advanced solid tumors. SNS-314 is expected tobegin Phase 1 clinical trials in the first half of 2007. I...

Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR

...withnon-Hodgkin's lymphoma and chronic lymphocytic leukemia later thisyear at cancer centers in the United States. About GS 9219 GS 9219 is a prodrug of the nucleotide analog PMEG(9-(2-phosphonylmethoxyethyl)guanine). It is selectively enrichedin lymphocytes, and therefore may have potential applications ...

Major Gene Study Uncovers Secrets of Leukemia

...e to the formation of pediatricacute lymphoblastic leukemia (ALL), the most common cancer inchildren. The disc...e. The St. Jude group used this approachto analyze leukemia samples from 242 pediatric patients with ALL.This identified an unexpectedly high frequency of mutat...